JPMorgan Starts Structure Therapeutics (GPCR) at Overweight

May 21, 2024 2:46 AM EDT Send to a Friend
JPMorgan analyst Hardik Parikh initiates coverage on Structure Therapeutics (NASDAQ: GPCR) with a Overweight rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login